CIRM Funded Clinical Trials

A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA

Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$11,637,194
Trial Sponsor:
Genascence Corporation
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A